Abstract: The invention is directed to emulsifiable oil suspension concentrate formulations containing cinnamaldehyde (cinnamic aldehyde) and allicin that are effective in protecting plants from pests, especially nematodes, and methods of their use.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
October 20, 2015
Assignee:
Valent BioSciences Corporation
Inventors:
Bala N. Devisetty, Bassam Shammo, Linda A. Rehberger, Rebecca Dickenson, Heemanshubhai K. Patel, Daniel F. Heiman
Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
Abstract: The present invention provides the use of a UV absorber for reducing the E/Z isomerization of pesticides comprising a double bond. It furthermore relates to a composition comprising an E and/or a Z isomer of a pesticide comprising a double bond and a UV absorber.
Type:
Grant
Filed:
April 13, 2011
Date of Patent:
September 8, 2015
Assignee:
BASF SE
Inventors:
Michael Ishaque, Vijay Narayanan Swaminathan, Sylke Haremza, Claude Taranta, William Baxter
Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
August 18, 2015
Assignee:
INFINITY PHARMACEUTICALS, INC.
Inventors:
Julian Adams, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
Abstract: Described is a solubilizate of a preservative containing an aliphatic and/or aromatic acid such as sorbic acid and/or benzoic acid that is free of stabilizing agents, as well as one or more emulsifiers with an HLB value between 9 and 18 with a concentration of about 50% and about 95% emulsifier with regard to the total quantity of the solubilizate, and a procedure for the production of such a solubilizate.
Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.
Type:
Grant
Filed:
February 28, 2012
Date of Patent:
August 4, 2015
Assignee:
Senju Pharmaceutical Co., Ltd.
Inventors:
Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
Abstract: The invention discloses 4-(arylamino)selenophenopyrimidine derivatives of formula (I), hydrates, solvates, isomers, or pharmaceutically acceptable salts thereof; process for their preparation and methods of treating or inhibiting or controlling a cell proliferative disorders, particularly cancer using said compounds. Pharmaceutical compositions comprising 4-(arylamino)selenophenopyrimidine derivatives of formula (I) are useful for the treatment, inhibition, or control of cancer.
Abstract: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an ?2 adrenergic receptor agonist.
Abstract: Composition of vitamin D in medium-chain triglycerides and use thereof in delivering a nutritional or therapeutic amount of vitamin D to a human being, particularly, an infant. The compositions are applied to an object, such as skin or in the case of an infant to a woman's nipple or pacifier from which the infant sucks off the composition. The method provides a more suitable, safer and efficient way of providing the human being with vitamin D. The compositions further comprise a free fatty acid and/or monoglyceride, oxidant preservative and, optionally, other vitamins.
Abstract: The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
June 30, 2015
Assignee:
The United States of America as Represented by the Department of Veterans Affairs
Abstract: The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
April 24, 2013
Date of Patent:
June 30, 2015
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Robert Murray McKinnell, Daniel D. Long
Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
Type:
Grant
Filed:
June 19, 2014
Date of Patent:
June 9, 2015
Assignee:
The Regents of the University of California
Inventors:
Dennis A. Carson, Howard B. Cottam, Wolfgang Wrasidlo, Christina C. N. Wu, Gregory A. Daniels
Abstract: A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.
Abstract: Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-K? and showed by 2?(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern has characteristic absorption peaks at about 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm-1, and its DSC endothermic transition temperature is 97.6° C. The use of the agomelatine crystal as an active ingredient in preparing a medicament for the treatment of depression is also provided.
Type:
Grant
Filed:
December 13, 2010
Date of Patent:
May 12, 2015
Assignee:
Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd.
Abstract: The present invention provides a process for preparing a compound of formula (VI) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an ?-haloketone of formula (III) to produce the compound of formula (IV); (iii) reducing the compound (IV) to a compound of formula (V); and (iv) reducing the compound (V) to the compound of formula (VI), wherein the reduction is carried out in the presence of either (1) a hydrogen donating compound in the presence of a hydrogen transfer catalyst; or (2) ammonium formate using a hydrogenation catalyst, wherein R1 and R2 are independently optionally substituted arylalkyl, and Hal is selected from chloro or bromo.
Abstract: Pyrazolone derivative formulations are provided. The formulations include a pyrazolone derivative active agent, e.g., edaravone, and an amphiphilic solubilizing agent. Also provided are methods of making and using the subject formulations.
Type:
Grant
Filed:
November 18, 2009
Date of Patent:
April 14, 2015
Assignees:
Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.
Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
Type:
Grant
Filed:
February 14, 2013
Date of Patent:
April 7, 2015
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Fariborz Firooznia, Tai-An Lin, Eric Mertz, Sung-Sau So, Achyutharao Sidduri, Jefferson Wright Tilley
Abstract: The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.
Type:
Grant
Filed:
February 9, 2010
Date of Patent:
March 31, 2015
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
Inventors:
Eli Breuer, Reuven Reich, Julia Frant, Amnon Hoffman, Veerendhar Ainelly
Abstract: PDE10 inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit PDE10 are also disclosed.
Type:
Grant
Filed:
June 25, 2012
Date of Patent:
March 10, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
William D. Schmitz, Mikkel V. DeBenedetto, S. Roy Kimura
Abstract: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.